Mechanisms of action and resistance for multiple myeloma novel drug treatments
- 1.6k Downloads
KeywordsMultiple Myeloma Chronic Myeloid Leukemia Thalidomide Bortezomib Lenalidomide
Multiple myeloma (MM) is an incurable plasma cell malignancy that develops as a result of multistep tumorigenic events . The median overall survival of patients with newly diagnosed MM was approximately 2.5–3 years when melphalan and prednisone (MP) therapy was the standard of care. However, since the end of the 20th century, genetic and epigenetic alterations associated with the pathogenesis of MM and tumor cell biology of the bone marrow microenvironment have been gradually unraveled [2, 3]. In parallel, the discovery of thalidomide as an active agent for MM in 1999 ushered in a new era in the treatment of this intractable disease . This was followed by the clinical application of bortezomib, a first-generation proteasome inhibitor (PI), based on the results of pre-clinical translational studies [3, 5]. Novel thalidomide derivatives called immunomodulatory drugs (IMiDs), such as lenalidomide and pomalidomide, were also developed [6, 7]. Second-generation PIs, such as carfilzomib and ixazomib, have recently been approved by the FDA . Currently, PIs and IMiDs, as well as corticosteroid and alkylating agents, are the key novel drugs for MM treatment which have resulted in the achievement of a median survival of approximately 5–6 years . Moreover, additional agents with different mechanisms of action have been incorporated into the treatment of MM, including the deacetylase inhibitor panobinostat and monoclonal antibodies, targeting SLAMF7, CD38, and PD-1 represented by elotuzumab, daratumumab/isatuximab, and pembrolizumab/nivolumab, respectively [10, 11]. Thus, the prognosis of patients with MM is expected to continue to improve.
Interestingly, however, the mechanisms of action of these new agents for MM have not been fully elucidated. These new agents are completely different from such drugs as tyrosine kinase inhibitors (TKIs), which are used in the treatment of chronic myeloid leukemia (CML), because the target molecule is not well specified . When thalidomide was induced, the inhibitory effect on angiogenesis and TNFα production were considered attributable to its anti-MM activity. When the PI bortezomib was being studied in clinical trials, it was believed that the inhibitory effect on NF-κB signaling, via the prevention of degradation of poly-ubiquitinated IκB, was attributed to the robust killing activity on MM cells. Sparked by the great discovery that cereblon was the molecule responsible for binding to thalidomide and causing its teratogenicity, it is now known that IMiDs induce the apoptosis of MM cells through the down-regulation of IRF4, via the cereblon-dependent ubiquitination of IKZF1 (Ikaros) and IKZF3 (Aiolos) which are transcription factors that are known to play an essential role in lymphocyte differentiation [13, 14]. Poly-ubiquitinated IKZF proteins caused by the altered substrate specificity of cereblon are degraded in the proteasome, resulting in the decreased transcription of IRF4 [15, 16]. At least one of the main mechanisms of bortezomib responsible for inducing apoptosis in MM cells is now considered to be excessive ER stress triggered by proteasome inhibition [17, 18]. The deacetylase inhibitor panobinostat not only inhibits major classes of histone deacetylases (HDAC), but also inhibits HDAC6, which is involved in the aggresome pathway and acetylates various critical proteins, such as TP53, Hsp90, and HIF-1α . Thus, the critical mechanisms of action of these novel agents in MM cells in association with the bone marrow microenvironment have just begun to be understood.
The complete elucidation of the mechanisms of action of novel agents used in MM treatment is important for two reasons. First, the patients with MM eventually relapse after novel agent-containing therapies and they often show acquired resistance against these agents at the time of relapse. Even though this is a crucial clinical problem, the detailed mechanisms responsible for this type of resistance are unknown. To elucidate the molecular mechanisms of action for each novel agent is expected to lead to figuring out a treatment strategy to overcome this resistance. Second, the elucidation of the mechanisms of action for each agent can lead to the development of additional novel drugs and identify novel target molecules in MM cells and the bone marrow microenvironment. In other words, true molecular targeting drugs for MM, which are like the TKIs in CML, could be developed in the near future.
In this review series in Progress in Hematology, we have invited four authors who are actively involved in basic or translational research focused on this issue.
Compliance with ethical standards
Conflict of interest
S.I. received an honorarium from Celgene K.K., Janssen Pharmaceutical K.K., Bristol-Myers Squibb, Takeda Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. S.I. also received research funding from Kyowa Hakko Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Celgene K.K., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Teijin Pharma, Astellas Pharma Inc., Toyama Chemical Co. Ltd. Bayer Yakuhin Ltd., and Sanofi K.K.
- 7.San-Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.CrossRefPubMedGoogle Scholar
- 8.Dimoloulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. Lancet Oncol. 2016;17:27–38.CrossRefGoogle Scholar
- 10.San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimoloulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.CrossRefPubMedGoogle Scholar
- 15.Fisher ES, Böhm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49–53.Google Scholar